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329 Reactive hypoglycemia in non-diabetic cystic ﬁbrosis patients
J.M. van den Berg1, H.G. Heijerman1. 1Pulmonology Department, Haga Teaching
Hospital, The Hague, Netherlands
Background: CF patients may develop hypoglycemia during oral glucose tolerance
testing (OGTT). We investigated the clinical importance of this by prolonged OGTT
and continuous glucose monitoring system (CGMS).
Methods: Patients with reactive hypoglycemia on yearly OGTT (glucose
<3.3mmol/l) received a prolonged OGTT for 4 hours with regular determination
of plasma glucose, insulin, glucagon, and C-peptide levels. Next, they received a
subcutaneous CGMS for 3 days that measures interstitial glucose levels.
Results: 5 out of 75 CF patients (6.7%) had reactive hypoglycemia on yearly OGTT.
On prolonged OGTT, the 2 male and 3 female patients had a mean fasting glucose of
5.3mmol/l (SD 0.5). During the test mean glucose levels were 6.4mmol/l (SD 2.9).
Peak glucose levels (9.8−12.0mmol/l) were measured after 30−60 minutes. The
lowest glucose levels (2.0−3.1mmol/l) were measured in 4 patients after 150
minutes and in 1 patients after 240 minutes. Glucose levels returned to normal
afterwards. In all patients insulin levels (31.0−56.0 mU/l) peaked at least 30 minutes
after the glucose level peak. Insulin and C-peptide levels had parallel trends.
Glucagon levels were within the normal range and increased on low glucose levels.
In all patients CGMS results were within the normal range, with all glucose levels
between 3.9 and 11.1mmol/l.
Conclusion: In all patients blood insulin peaks were later than peaks in glucose
levels on prolonged OGTT, which indicates delayed insulin release. Glucose levels
found during OGTT were borderline to diabetes, although the CGMS revealed
no clinical implication in daily life. Patients with reactive hypoglycemia have
direct postprandial hyperglycemia due to a late insulin reaction. Therefore, reactive
hypoglycemia may be an indicator for patients who are at risk for developing CFRD.
330* Proof of principle. Treatment of cystic ﬁbrosis-related diabetes:
a possible role for complementary metformin?
J.M. van den Berg1, H.G. Heijerman1. 1Pulmonology Department, Haga Teaching
Hospital, The Hague, Netherlands
Background: Insulin therapy is standard medical treatment in cystic ﬁbrosis-related
diabetes (CFRD). However, peripheral insulin resistance due to inﬂammation and
drugs often complicates CFRD. Addition of an oral glucose-lowering agent with
the aim to lower peripheral insulin resistance may therefore reduce the need for
insulin and may improve glycemic control.
Methods: Metformin is a biguanide that acts on hepatic glucose production,
glucose intestinal resorption and glucose muscle uptake. Possible side effects are
gastrointestinal symptoms and a very small risk of lactic acidosis.
Two adult female cystic ﬁbrosis (CF) patients with long term CFRD and treated with
insulin pump therapy, had a disturbed glycemic control due to multiple pulmonary
exacerbations and in one case oral corticosteroid use. Metformin was given in
increasing dosages up to three times daily 500mg during meals.
Results: In both patients insulin need decreased dramatically. After 3 months basal
insulin need was decreased from 47 units per day (U/day) and 34 U/day to 35 U/day
(−26%) and 24 U/day (−29%) respectively. Bolus insulin need also decreased from
a mean of 38 U/day to 27 U/day (−29%) and from a mean of 18 U/day to 5 U/day
(−72%). There was no nausea observed and blood lactate levels remained normal
during metformin use.
Conclusion: In both patients insulin need decreased dramatically after starting
metformin. This pilot is promising for the treatment of CFRD in the future.
Currently a study is conducted to evaluate the effect of additional metformin on
insulin need and glycemic control in a large CFRD patient population.
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and Glucide Intolerance
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In this multicentric, randomized, controlled study, tolerability and efﬁcacy of
insulin glargine to improve nutritional and glicometabolic condition and respiratory
function was evaluated in CF patients with Glucide Intolerance (GI). Patients
were divided into two groups (Group A and Group B) and patients in Group
A received insulin (0.2U/K/die). Up to now 45 patients (23 in Group A and
22 in Group B) entered in the study for a mean period of 14 months (range
3−18 months). After the enrollment 11 patients interrupted the study: 6 patients
didn’t accept the randomization result, 1 patient developed overt diabetes after
9 months, 1 patient voluntarily interrupted the drug after 15 months, 1 patient
started enteral nutrition after 15 months, 1 underwent lung transplantation after
6 months, 1 died after 6 months. The collected data have been considered for all
the paramethers at time +9 months. Friedman’s test was performed. BMI, Weight
and FEV1% showed a mean improvement in group A patients (+0.3, +1 kg, +6%
respectively), and a mean worsening in Group B (−0.1, −0.3 kg, −2.5% respectively).
No difference reached statistical signiﬁcance. Patients in both Groups improved
their glicometabolic condition, but improvement in patients of group A was higher,
even if not signiﬁcantly (−0.2% and −0.1% respectively). No adverse effects were
reported.
In conclusion insuline glargine has shown an apparently good impact on gli-
cometabolic and clinical condition of underlying disease in CF patients with GI.
Glargine, at the studied dosage, showed to be safe and well-accepted.
Supported by: Italian CF Research Foundation.
332 Carbohydrate counting and insulin adjustment in Cystic Fibrosis
related Diabetes
L. Robb1, M. Richardson1, S. Johnston1, J.A. Innes1. 1Scottish Adult Cystic
Fibrosis Service, Western General Hospital, Edinburgh, United Kingdom
Introduction: Carbohydrate (CHO) counting & insulin adjustment programmes
teach participants to match insulin doses to food choices, whilst keeping blood
glucose levels within the individuals target range.
CHO counting resources used locally were considered inappropriate for patients
with Cystic Fibrosis (CF) due to their group format, “healthy eating” focus & lack
of evaluation in the treatment of CF related diabetes (CFRD).
Aim: Develop & evaluate a CHO counting & insulin adjustment education pro-
gramme for CFRD patients.
Methods: CHO counting/insulin adjustment skills were acquired via training
courses & shadowing. A CHO counting programme speciﬁcally for patients with
CFRD was developed and literature for those on conventional treatment was
updated. Inclusion: patients on short acting daily insulin injections for  3 months.
Controls: patients wishing to remain on conventional treatment.
Both groups are seen at baseline, 3/12, 6/12, 9/12, 12/12. The study group
(SG) are educated using the programme. The control group (CG) are re-educated
using the updated literature. Outcome measures: body mass index (BMI), HBA1c,
hypoglycaemic episodes (HE) & evaluation tool results. We intend to compare the
two groups once data collection is complete.
Discussion:We hope to recruit  15 patients into each group prior to data analysis.
Results look promising so far, with an improvement in BMI (mean ↑ 0.3 SG, ↑ 0.2
CG) & HBA1c (mean ↓ 0.5% SG, no change CG) & a reduction in HE (mean
↓ 2.5 HE per month SG, ↑ 1 CG). Food knowledge is enhanced and patients appear
to have better insight into diabetes treatment, targets and importance of good control.
Some ﬁnd the demands of the programme excessive, although the majority ﬁnd the
programme worthwhile.
